CANCER RESEARCH (CHICAGO, ILL.)

Visão geral
Metrics
Identidade
Ver todos

Qualis

A1

código do país

US

tipo

journal

publicação venue de

β-catenin-driven differentiation is a tissue-specific epigenetic vulnerability in adrenal cancer. 2:2123-2141. 2023-01-01
A national survey of current scenario and future perspectives of cancer research in Brazil.. 41:e18721. 2023-01-01
Abstract 2114: Salivary glands shedding RNA into saliva: Challenges and opportunities. 83:2114-2114. 2023-01-01
Abstract 2121: Saliva TCR repertoire as a tool for head and neck cancer immunophenotype monitoring. 83:2121-2121. 2023-01-01
Abstract 2175: Gene signature predicts pathological complete response in triple negative breast cancer patients: NACATRINE trial. 83:2175-2175. 2023-01-01
Abstract 2855: Epithelial-mesenchymal transition profile after cisplatin-resistance induction in OSCC cell line. 83:2855-2855. 2023-01-01
Abstract 3752: The role of miR-200 in anaplastic thyroid cancer aggressiveness. 83:3752-3752. 2023-01-01
Abstract 4192: : A precision DNA methylation test to identify advanced disease risk in cervical cancer screening algorithms. 83:4192-4192. 2023-01-01
Abstract 4723: DNA G-quadruplex facilitates MYC enhancer-promotor interaction. 83:4723-4723. 2023-01-01
Abstract 55: High frequency of TP53 mutations in canine skin tumors recapitulates solar induced human lesions representing an important research model of spontaneous diseases. 83:55-55. 2023-01-01
Abstract 6528: HPV status and epigenetic profiling of saliva from a cancer-free population. 83:6528-6528. 2023-01-01
Abstract 6544: Identification of epigenetic regulatory networks associated with the basal-like breast cancer subtype. 83:6544-6544. 2023-01-01
Abstract 934: Use of real-world data of dogs with cancer to drive drug development strategy and inform human clinical trials. 83:934-934. 2023-01-01
Abstract GS4-02: Oncological Outcomes Following Omission of Axillary Lymph Node Dissection in Node Positive Patients Downstaging To Node Negative with Neoadjuvant Chemotherapy: the OPBC-04/EUBREAST-06/OMA study. 83:GS4-02-GS4-02. 2023-01-01
Abstract LB107: A precision DNA methylation test to triage HPV positive women before referral to colposcopy-driven biopsies or ablative treatment in cervical cancer screening clinics worldwide. 83:LB107-LB107. 2023-01-01
Abstract OT1-18-01: COMPARATIVE ANALYSIS BETWEEN ACUPUNCTURE AND EXERCISE IN IMPROVING DERMAL SENSITIVITY DURING PACLITAXEL-CONTAINING CHEMOTHERAPY: A RANDOMIZED CLINICAL TRIAL. 83:OT1-18-01-OT1-18-01. 2023-01-01
Abstract OT2-22-02: Sequencing of anthracyclines and taxanes during neoadjuvant therapy of locally advanced HER2-negative breast cancer (NEOSAMBA Study/LACOG 0419). 83:OT2-22-02-OT2-22-02. 2023-01-01
Abstract OT3-07-01: Real-World Data on First-line Treatment of HR-positive, HER2-negative, Metastatic Breast Cancer in Brazil (BRAVE Study/LACOG 0221). 83:OT3-07-01-OT3-07-01. 2023-01-01
Abstract P1-10-03: Ultra-hypofractionated Radiotherapy for Breast Cancer: A Brazilian Single-Institutional Series. 83:P1-10-03-P1-10-03. 2023-01-01
Abstract P2-11-03: How to make decisions in ductal carcinoma in situ? The first study of clinical applicability of the MSKCC ductal carcinoma in situ nomogram in the prediction of local recurrence risk after breast conserving surgery in a Brazilian cohort. 83:P2-11-03-P2-11-03. 2023-01-01
Abstract P2-14-11: Oncological outcomes in patients undergoing targeted axillary dissection with carbon marker. 83:P2-14-11-P2-14-11. 2023-01-01
Abstract P2-14-16: Breast surgery for metastatic breast cancer: a Cochrane systematic review. 83:P2-14-16-P2-14-16. 2023-01-01
Abstract P2-14-18: Oncological Outcomes of Nipple-Sparing Mastectomy after Neoadjuvant Chemotherapy. 83:P2-14-18-P2-14-18. 2023-01-01
Abstract P2-17-02: SMC6 down-regulation: marker of genetic instability and poor outcome in breast cancer. 83:P2-17-02-P2-17-02. 2023-01-01
Abstract P3-05-12: A matched cohort study of the prognosis of early breast cancer in patients with Li-Fraumeni syndrome. 83:P3-05-12-P3-05-12. 2023-01-01
Abstract P3-05-13: INFLUENCE OF METABOLIC SYNDROME ON OVERALL SURVIVAL (OS), DISEASE FREE SURVIVAL (DFS) AND INVASIVE FREE SURVIVAL (IFV) IN A COHORT OF PATIENTS TREATED FOR BREAST CANCER IN BRAZIL. 83:P3-05-13-P3-05-13. 2023-01-01
Abstract P3-05-37: Influence of Clinical Heterogeneity on Pregnancy Associated Breast Cancer survival: Systematic Review with Metanalysis. 83:P3-05-37-P3-05-37. 2023-01-01
Abstract P3-05-53: IMPACT OF THE BODY MASS INDEX (BMI) ON THE SURVIVAL OF BREAST CANCER WOMEN WHO ACHIEVED A COMPLETE PATHOLOGICAL RESPONSE (pCR) AFTER NEOADJUVANT CHEMOTHERAPY (NACT) IN BRAZIL. 83:P3-05-53-P3-05-53. 2023-01-01
Abstract P4-03-41: Prospective observational study of breast cancer patients during the cycle of chemotherapy with taxanes: evaluation of the incidence and prevalence of peripheral neuropathy. 83:P4-03-41-P4-03-41. 2023-01-01
Abstract P4-07-10: Effect of acupuncture and exercise therapy on muscular strength, lymphedema and quality of life in breast cancer survivors: randomized clinical trial. 83:P4-07-10-P4-07-10. 2023-01-01
Abstract P4-07-43: Effect of acupuncture and exercise therapy in rehabilitation of physical disfunctions in breast cancer survivors: randomized clinical trial. 83:P4-07-43-P4-07-43. 2023-01-01
Abstract P4-07-44: Association between tissue mobilization with physical exercise and physical exercise alone in patients with axillary web syndrome who underwent breast cancer surgery. 83:P4-07-44-P4-07-44. 2023-01-01
Abstract P4-07-48: Preliminary results of the FIRST (FreezIng bReaST cancer in Brazil) trial: a before-after study. 83:P4-07-48-P4-07-48. 2023-01-01
Abstract P4-07-61: Lymphedema, shoulder range of motion, pain, and presence of cords in patients undergoing breast cancer treatment with axillary web syndrome: Late follow-up. 83:P4-07-61-P4-07-61. 2023-01-01
Abstract P5-01-09: Evaluation of the efficacy of using fluorescence-associated indocyanine green in sentinel lymph node biopsies from breast cancer patients. 83:P5-01-09-P5-01-09. 2023-01-01
Abstract P5-04-02: Comparative analysis between screening mammography performed in patients at usual risk and patients at high risk for breast cancer in the early detection program for breast cancer in Brazil. 83:P5-04-02-P5-04-02. 2023-01-01
Abstract P5-13-01: TUMOR PROGRESSION MODEL IN BREAST CANCER WITH BRAIN METASTASIS. 83:P5-13-01-P5-13-01. 2023-01-01
Abstract P6-13-01: EPITHELIAL-MESENCHYMAL TRANSITION AND TUMOR STEM CELLS NETWORK IDENTIFICATION IN BREAST CARCINOMAS: IN SILICO STUDY. 83:P6-13-01-P6-13-01. 2023-01-01
Oncological outcomes in patients undergoing targeted axillary dissection with carbon marker. 83:suplemento. 2023-01-01
Abstract 157: DUSP6 modulates migration and glycolysis in PDAC cells. 82:157-157. 2022-01-01
Abstract 2226: Using functional biomarkers to accurately predict advanced neoplasia in pancreatic cystic lesions. 82:2226-2226. 2022-01-01
Abstract 2387: The impact of beta 1,6-GlcNAc branched -glycan synthesis on hexosamine pathway and UDP-GlcNAc demands in colorectal cancer cells. 82:2387-2387. 2022-01-01
Abstract 3097: Patient-derived renal cell carcinoma xenografts engraftment identifies patients at risk of disease relapse, progression and death. 82:3097-3097. 2022-01-01
Abstract 6095: SMOC2 as a potential biomarker with diagnostic value in uterine leiomyosarcoma. 82:6095-6095. 2022-01-01
Abstract 6098: Analysis of the impact of ZEB1 expression on pathway enrichment and immune cell abundance in prostate cancer. 82:6098-6098. 2022-01-01
Abstract 6099: Differential gene expression related to TMPRSS2-ERG fusion, CDK12, RB1, TP53, AR and ZEB1 based on transcriptomic analysis of the TCGA PRAD cohort. 82:6099-6099. 2022-01-01
Abstract 635: Concordance between dogs and humans: The use of AI in evaluating clinical cancer genomic datasets. 82:635-635. 2022-01-01
Abstract OT2-22-02: Sequencing of anthracyclines and taxanes during neoadjuvant therapy of locally advanced HER2-negative breast cancer (NEOSAMBA Study/LACOG 0419). 83:1538-7445-OT2-22-02. 2022-01-01
Abstract OT3-07-01: Real-World Data on First-line Treatment of HR-positive, HER2-negative, Metastatic Breast Cancer in Brazil (BRAVE Study/LACOG 0221). 83:1538-7445. 2022-01-01
Abstract P1-13-04: Evaluation of the impact Vitamin D and Calcium supplementation on bone mineral density in breast cancer patients using or not taking Aromatase Inhibitors: 5-year follow-up. 82:P1-13-04-P1-13-04. 2022-01-01
Abstract P2-07-11: Application of the genetic signature MammaPrint- in the Brazilian population - Real-world study (AGEMA-BRA). 82:P2-07-11-P2-07-11. 2022-01-01
Abstract P3-15-04: How can we help: The needs of those seeking breast cancer information and support from a cancer patient advocacy organization in Brazil. 82:P3-15-04-P3-15-04. 2022-01-01
Abstract P4-10-05: Safety and efficacy of low dose topical testosterone for sexual function improvement in women with breast cancer under treatment with ovarian suppression and aromatase inhibitor. 82:P4-10-05-P4-10-05. 2022-01-01
Abstract P4-11-17: Return to work after breast cancer: Disparities among patients treated in public and private hospitals in Brazil. 82:P4-11-17-P4-11-17. 2022-01-01
Abstract P4-12-14: Assessing patients perceptions on hormone therapy for breast cancer: Insights from a Brazilian patient group. 82:P4-12-14-P4-12-14. 2022-01-01
Biópsia do linfonodo sentinela versus seguimento clínico axilar em mulheres com câncer de mama inicial com axila negativa aos exames clínico e ultrassonográfico. 82:03-04. 2022-01-01
Preclinical Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification. 82:1646-1657. 2022-01-01
Abstract 2290: The serine-threonine kinase Mink1 as a potential therapeutic target in triple negative breast cancer. 81:2290-2290. 2021-01-01
Abstract 2991: Mutational screening of BRCA1/2 genes in 667 spontaneous canine tumors. 81:2991-2991. 2021-01-01
Abstract 801: Acute leukemia excess in families. 81:801-801. 2021-01-01
Abstract CT255: Canakinumab as adjuvant therapy in patients with completely resected non-small cell lung cancer: CANOPY-A trial. 81:CT255-CT255. 2021-01-01
Abstract GS3-04: Double-blind placebo (PBO)-controlled randomized phase III trial evaluating first-line ipatasertib (IPAT) combined with paclitaxel (PAC) for -altered locally advanced unresectable or metastatic triple-negative breast cancer (aTNBC): primary results from IPATunity130 Cohort A. 81:GS3-04-GS3-04. 2021-01-01
Abstract LB120: A novel peptide-drug conjugate induces DNA damage in SSTR2-expressing cells. 81:LB120-LB120. 2021-01-01
Abstract PS1-44: Impact of a standardized protocol for management of axilla after neoadjuvant chemotherapy in breast cancer patients at a cancer center. 81:PS1-44-PS1-44. 2021-01-01
Abstract PS13-25: Management of abemaciclib associated diarrhea in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: Analysis of the MONARCH plus study. 81:PS13-25-PS13-25. 2021-01-01
Abstract PS9-37: Hereditary breast and ovarian cancer syndrome (HBOC) diagnosis impacts more the life quality of women than men: A case-control report. 81:PS9-37-PS9-37. 2021-01-01
Catecholamines Mediate Psychologic Stress-Induced Cancer Progression. 81:5144-5146. 2021-01-01
Deciphering the Role of Intestinal Crypt Cell Populations in Resistance to Chemotherapy. 81:2730-2744. 2021-01-01
Genome-wide DNA methylation profiling of esophageal squamous cell carcinoma from global high-incidence regions identifies crucial genes and potential cancer markers. 1:2612-2624. 2021-01-01
Peripheral Nerve Resident Macrophages and Schwann Cells Mediate Cancer-induced Pain. 81:3387-3401. 2021-01-01
The Common Germline TP53-R337H Mutation is Hypomorphic and Confers Incomplete Penetrance and Late Tumor Onset in a Mouse Model. 81:2442-2456. 2021-01-01
The Origins of Phenotypic Heterogeneity in Cancer. 81:3-11. 2021-01-01
Unraveling the Mysteries of PAX8 in Reproductive Tract Cancers. 81:806-810. 2021-01-01
A high-content screen identifies drugs that restrict tumor cell extravasation across the endothelial barrier. 81:canres.3911.20-633. 2020-01-01
A rare TP53 mutation predominant in Ashkenazi Jews confers risk of multiple cancers. x:canres.1390.2020. 2020-01-01
Abstract 5486: Time-dependent mathematical modeling of genetic alterations in acute myeloid leukemia. 80:5486-5486. 2020-01-01
Abstract CT286: CANOPY program clinical trials: Canakinumab (Cana) in patients (pts) with non-small cell lung cancer (NSCLC). 80:CT286-CT286. 2020-01-01
Abstract CT287: CANOPY-A: A phase III, multicenter, randomized trial evaluating canakinumab versus placebo as adjuvant therapy in patients with completely resected non-small cell lung cancer (NSCLC). 80:CT287-CT287. 2020-01-01
Accuracy of ultrasound-guided fine needle aspiration citology (US-FNAC) to detect axillary involvement in breast cancer. 80:1-p4-02-14. 2020-01-01
BRD4 levels determine the response of human lung cancer cells to BET degraders that potently induce apoptosis through suppression of Mcl-1. xXX:canres.3674.2019. 2020-01-01
Cancer Cell Fitness Is Dynamic. 1:1040-1051. 2020-01-01
Epigenetic Repression in Tumor-Associated Fibroblasts Impairs Fibrosis and Response to the Antifibrotic Drug Nintedanib in Lung Squamous Cell Carcinoma. 80:276-290. 2020-01-01
Galectin-3 and the modulation of autophagy in the pancreatic cancer microenvironment. 80:1241-1241. 2020-01-01
In Situ DESI-MSI Lipidomic Profiles of Breast Cancer Molecular Subtypes and Precursor Lesions. 1:1246-1257. 2020-01-01
Mass Spectrometry Imaging Enables Discrimination of Renal Oncocytoma from Renal Cell Cancer Subtypes and Normal Kidney Tissues. 80:689-698. 2020-01-01
Model-based inference and classification of immunological control mechanisms from TKI cessation and dose reduction in CML patients. 80:canres.2175.20. 2020-01-01
Targeting the E3 Ubiquitin Ligase PJA1 Enhances Tumor-Suppressing TGFβ Signaling. 80:1819-1832. 2020-01-01
Therapy-Induced Senescence Drives Bone Loss. 80:1171-1182. 2020-01-01

tem uma área de assunto

publisher

American Association for Cancer Research

is open access

False invalid format

is in DOAJ

False invalid format